<DOC>
	<DOCNO>NCT00469079</DOCNO>
	<brief_summary>The use smokeless tobacco ( ST ) substitute cigarette smoking suggest since consider less harmful tobacco product ( Russell , Jarvis Feyerabend , 1980 ; Russell et al , 1981 ; Rodu , 1994 ) . ST volatile constituent carbon monoxide ( CO ) find cigarette smoke . Since ST smoke would less risk cardiovascular lung disease . In addition harm associate second hand smoke would eliminate . Although health risk reduce ST user , still exist due presence nitrosamines find ST. A good approach would use nicotine replacement contain carcinogen , however cost NRT could prohibitive especially third world country rate smoking continue rise per capita income much low United States . Purpose : The goal study evaluate health effect Camel Snus , new oral tobacco product produce RJ Reynolds Taboka , produce Phillip Morris . These product pasteurize rather ferment contain less moisture eliminate spit . They market alternative cigarette smoking .</brief_summary>
	<brief_title>Health Effects SLT , Cigarette Smoking , New Tobacco Products</brief_title>
	<detailed_description>Cigarette smoker ( n=125 ) recruit local metropolitan area use multiple medium outlet . Subjects medically psychologically healthy recruit study . Cigarette smoker inform study telephone ask answer brief tobacco use history medical screening questionnaire . If subject pass initial screening study , ask attend orientation meeting Tobacco Use Research Center study explain detail , informed consent obtain full screen evaluation occur . This evaluation include completion several comprehensive tobacco use social history form complete physical psychological screening . Subjects require attend clinic Week 1 Week 2 study order obtain baseline data . At end Week 2 , cigarette smoker randomly assign either : 1 ) quit tobacco use offer choice use nicotine gum lozenge , depend personal preference ( n= 25 ) assign switch : 2 ) Taboka ( n=50 ) 3 ) Camel Snus ( n=50 ) . Subjects sample different flavor product 1 week use product next 4 week . During four week , subject ask attend weekly clinic visit time study data collect . After 4 week study product use , subject require taper tobacco nicotine product next one week cease tobacco use . Follow-up visit conduct 1 week 11 week completion study outcome measure take time . Blood urine sample collect analyzed tobacco related toxicant treatment period .</detailed_description>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<mesh_term>Lobeline</mesh_term>
	<criteria>Subjects 1870 year age Smoking least 10 cigarettes/day least one year Good physical mental health evidence medical history unstable medical condition . Uncontrolled chronic disease condition require medical attention course study Contraindications nicotine replacement product : active ulcer , recent heart attack , heart disease irregular heart beat , uncontrolled high blood pressure , medication use might affect tobacco use Current unstable psychiatric diagnosis person currently adjust medication dose . ( within last 3 month ) Subjects current recent ( within 6 month ) alcohol drug abuse problem Other regular tobacco use regular cigar pipe smoke Currently use nicotine replacement product Chronic use drug could interact study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Biomarkers</keyword>
	<keyword>Smoking</keyword>
	<keyword>Tobacco</keyword>
	<keyword>Cessation</keyword>
</DOC>